Dogwood Therapeutics Inc
DWTX6.450USD
+0.350+5.74%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
14.79MMarket Cap
0.07P/E TTM
More Details of Dogwood Therapeutics Inc Company
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Dogwood Therapeutics Inc Info
Ticker SymbolDWTX
Company nameDogwood Therapeutics Inc
IPO dateDec 17, 2020
CEODuncan (Gregory Scott)
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 17
Address44 Milton Avenue
CityALPHARETTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30009
Phone18666208655
Websitehttps://dwtx.com/
Ticker SymbolDWTX
IPO dateDec 17, 2020
CEODuncan (Gregory Scott)
Company Executives of Dogwood Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Ralph Grosswald
Mr. Ralph Grosswald
Senior Vice President - Operations
Senior Vice President - Operations
--
--
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alan Yu
Mr. Alan Yu
Director
Director
--
--
Mr. John C. Thomas, Jr.
Mr. John C. Thomas, Jr.
Independent Director
Independent Director
--
--
Mr. David (Rick) Keefer
Mr. David (Rick) Keefer
Independent Director
Independent Director
--
--
Mr. Melvin Toh
Mr. Melvin Toh
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Ralph Grosswald
Mr. Ralph Grosswald
Senior Vice President - Operations
Senior Vice President - Operations
--
--
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
0.71%
Rejuvenation Labs, Inc.
0.64%
Serpin Pharma Inc
0.64%
Orca Capital GmbH
0.23%
The Vanguard Group, Inc.
0.07%
Other
97.69%
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
0.71%
Rejuvenation Labs, Inc.
0.64%
Serpin Pharma Inc
0.64%
Orca Capital GmbH
0.23%
The Vanguard Group, Inc.
0.07%
Other
97.69%
Shareholder Types
Shareholders
Proportion
Corporation
2.00%
Investment Advisor
0.31%
Investment Advisor/Hedge Fund
0.05%
Individual Investor
0.01%
Other
97.63%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
39
108.81K
4.95%
--
2025Q3
40
108.81K
5.96%
-4.30K
2025Q2
39
113.11K
5.28%
-38.77K
2025Q1
44
151.88K
3.29%
+89.03K
2024Q4
46
30.86K
5.46%
-11.80K
2024Q3
47
70.56K
12.43%
+3.12K
2024Q2
50
67.43K
14.68%
+12.42K
2024Q1
48
55.11K
21.02%
-106.80K
2023Q4
46
62.40K
20.78%
+1.23K
2023Q3
50
61.22K
20.44%
+1.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
CK Life Sciences International Holdings, Inc.
211.38K
11.06%
--
--
Apr 15, 2025
Orca Capital GmbH
69.82K
3.65%
+69.82K
--
Mar 14, 2025
The Vanguard Group, Inc.
11.78K
0.62%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
12.82K
0.67%
-1.59K
-11.01%
Jun 30, 2025
Duncan (Gregory Scott)
2.30K
0.12%
--
--
Apr 15, 2025
Tower Research Capital LLC
792.00
0.04%
-258.00
-24.57%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
600.00
0.03%
--
--
Jun 30, 2025
Keefer (David R)
512.00
0.03%
--
--
Apr 15, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
Date
Type
Ratio
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
Oct 07, 2024
Merger
25→1
FAQs
Who are the top five shareholders of Dogwood Therapeutics Inc?
The top five shareholders of Dogwood Therapeutics Inc are:
CK Life Sciences International Holdings, Inc. holds 211.38K shares, accounting for 11.06% of the total shares.
Orca Capital GmbH holds 69.82K shares, accounting for 3.65% of the total shares.
The Vanguard Group, Inc. holds 11.78K shares, accounting for 0.62% of the total shares.
Geode Capital Management, L.L.C. holds 12.82K shares, accounting for 0.67% of the total shares.
Duncan (Gregory Scott) holds 2.30K shares, accounting for 0.12% of the total shares.
CK Life Sciences International Holdings, Inc. holds 211.38K shares, accounting for 11.06% of the total shares.
Orca Capital GmbH holds 69.82K shares, accounting for 3.65% of the total shares.
The Vanguard Group, Inc. holds 11.78K shares, accounting for 0.62% of the total shares.
Geode Capital Management, L.L.C. holds 12.82K shares, accounting for 0.67% of the total shares.
Duncan (Gregory Scott) holds 2.30K shares, accounting for 0.12% of the total shares.
What are the top three shareholder types of Dogwood Therapeutics Inc?
The top three shareholder types of Dogwood Therapeutics Inc are:
CK Life Sciences International Holdings, Inc.
Rejuvenation Labs, Inc.
Serpin Pharma Inc
CK Life Sciences International Holdings, Inc.
Rejuvenation Labs, Inc.
Serpin Pharma Inc
How many institutions hold shares of Dogwood Therapeutics Inc (DWTX)?
As of 2025Q4, 39 institutions hold shares of Dogwood Therapeutics Inc, with a combined market value of approximately 108.81K, accounting for 4.95% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.01%.
What is the biggest source of revenue for Dogwood Therapeutics Inc?
In --, the -- business generated the highest revenue for Dogwood Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
